达格列净在2型糖尿病且肾功能保留患者标准化钠摄入下的利钠效应:DAPASALT试验结果
DAPASALT是一项机制性、非随机、开放标签研究,纳入14例接受标准化钠饮食(150 mmol/天)的2型糖尿病且肾功能保留患者,评估达格列净对钠排泄、24小时血压及体液容量的影响。结果显示达格列净未显著改变尿钠排泄,但显著降低24小时收缩压,且未显著改变血浆容量或细胞内液容量,仅细胞外液在治疗开始时变化。结论提示达格列净的降压效应可能不完全依赖于利钠和容量变化。
要点
- 标准化钠摄入下,达格列净未显著增加尿钠排泄。
- 达格列净显著降低24小时收缩压,治疗开始和结束时均明显。
- 达格列净未显著改变血浆容量或细胞内液容量,仅细胞外液短暂变化。
核心结论
- 在标准化钠摄入下,达格列净降低血压而未显著改变尿钠排泄,提示降压效应可能涉及利钠和容量变化以外的因素。
研究设计与样本
- DAPASALT为机制性、非随机、开放标签研究,纳入14例2型糖尿病且肾功能保留患者,接受 controlled 标准化钠饮食(150 mmol/天)。
- 研究评估达格列净治疗开始(第2-4天)、治疗结束(第12-14天)和随访(第15-18天)的钠排泄、24小时血压及体液容量变化。
主要发现
- 基线平均(SD)24小时钠排泄为150(32)mmol,治疗期间无显著变化:治疗开始时变化-7.0 mmol/24h(95%CI -22.4至8.4),治疗结束时变化2.1 mmol/24h(95%CI -28.8至33.0)。
- 基线平均24小时收缩压为128(10)mmHg,治疗开始时显著降低-6.1 mmHg(95%CI -9.1至-3.1;P<0.001),治疗结束时降低-7.2 mmHg(95%CI -10.0至-4.3;P<0.001)。
- 达格列净未显著改变血浆容量或细胞内液容量,细胞外液在治疗开始时变化-0.7 L(95%CI -1.3至-0.1;P=0.02)。
- 24小时尿糖排泄在达格列净治疗期间显著增加,随访期间逆转。
临床怎么用
- 对于2型糖尿病且肾功能保留患者,达格列净的降压效应可能不完全依赖利钠作用,临床降压获益需综合理解其机制。
局限性
- 研究为非随机、开放标签设计,样本量较小(14例),可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma volume contraction. Few studies have investigated this hypothesis, but none have assessed cumulative sodium excretion with SGLT2 inhibition during standardized sodium intake in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: The DAPASALT trial was a mechanistic, nonrandomized, open-label study in patients with type 2 diabetes with preserved kidney function on a controlled standardized sodium diet (150 mmol/day). It evaluated the effects of dapagliflozin on sodium excretion, 24-h blood pressure, and extracellular, intracellular, and plasma volumes at the start of treatment (ST) (days 2-4), end of treatment (ET) (days 12-14), and follow-up (FU) (days 15-18). RESULTS: Fourteen patients were included in the efficacy analysis. Mean (SD) baseline sodium excretion (150 [32] mmol/24-h) did not significantly change during treatment (change at ST: -7.0 mmol/24-h [95% CI -22.4, 8.4]; change at ET: 2.1 mmol/24-h [-28.8, 33.0]). Mean baseline 24-h systolic blood pressure was 128 (10) mmHg and significantly reduced at ST (-6.1 mmHg [-9.1, -3.1]; P < 0.001) and ET (-7.2 mmHg [-10.0, -4.3]; P < 0.001). Dapagliflozin did not significantly alter plasma volume or intracellular volume, while extracellular volume changed at ST (-0.7 L [-1.3, -0.1]; P = 0.02). As expected, 24-h urinary glucose excretion significantly increased during dapagliflozin treatment and reversed during FU. CONCLUSIONS: During standardized sodium intake, dapagliflozin reduced blood pressure without clear changes in urinary sodium excretion, suggesting that factors other than natriuresis and volume changes may contribute to the blood pressure-lowering effects.
引用
- Scholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 2020. PMID: 33318125. doi:10.2337/dc20-2604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。